Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Advanced Non-squamous Non-small-cell Lung Cancer · Advanced Squamous Non-Small Cell Lung Carcinoma · Metastatic Non-squamous Non Small Cell Lung Cancer · Metastatic Squamous Non-Small Cell Lung Carcinoma · Non-small Cell Lung Cancer · Non-small Cell Lung Cancer Stage III · Non-small Cell Lung Cancer Stage IV · Non-small Cell Lung Cancer Recurrent
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +9.7
3 insiders sold shares within a month
Since Nov 3, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 142 (planned)
- Started
- Sep 26, 2024
- Main results expected
- Feb 2027
- Fully finished
- Jul 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Blinded Independent Central Review (BICR)
Measured over: From date of randomization up to 12 months.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 9.7, since 2026-11-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06463665 · record last updated 2026-06-04 · checked 2026-11-09 15:47 UTC